Novo Nordisk is trading 4.03% down at $40.48 amid a sharp U.S. market sell-off on November 5, 2026.
- Major indexes are down more than 2%, with technology and semiconductor concerns adding to risk-off sentiment; no company-specific catalyst is confirmed.
- Novo Nordisk’s November 4 earnings report beat estimates and lifted full-year guidance, so it does not explain today’s drop.
- No trading-volume details were available.